Atara Biotherapeutics, Inc.·4

Jun 15, 4:02 PM ET

Yarema Kristin 4

4 · Atara Biotherapeutics, Inc. · Filed Jun 15, 2021

Insider Transaction Report

Form 4
Period: 2021-06-11
Yarema Kristin
Chief Commercial Officer
Transactions
  • Purchase

    Common Stock

    2021-06-11$14.50/sh+2,021$29,30593,549 total
  • Purchase

    Common Stock

    2021-06-14$14.48/sh+3,500$50,68097,049 total
  • Purchase

    Common Stock

    2021-06-14$14.58/sh+28,833$420,385125,882 total
Footnotes (1)
  • [F1]The reporting person's sale of ATRA common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 761 shares, with the reporting person's sale of 761 shares of ATRA common stock at a weighted average price of $14.55 per share on May 18, 2021. The reporting person has agreed to pay to ATRA $53.27, representing the full amount of the profit realized in connection with the short-swing transaction.

Documents

1 file
  • 4
    doc1.xmlPrimary

    FORM 4